NOT KNOWN DETAILS ABOUT HEMGENIX

Quantity of suitable sufferers: CDEC talked over the uncertainty in the quantity of sufferers with moderately critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some patients who are classified as owning gentle or average ailment may have a serious bleeding phenoty